1379TiPPhase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor. (18th September 2017) - Park, K.; Ciardiello, F.; Hida, T.; Lim, W.; Lin, C-C.; Murakami, H.; Nishio, M.; Cantero, F.; Cattan, V.; Gabarroca, C.; Gandossi, E.; Paz-Ares, L.